After months of warnings, FTC opens investigation into Teva over ‘improper’ patents

Taking stock of the drug industry, from the lab to the medicine chest

July 1, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Dan Balilty/AP STAT+ | After months of warnings, FTC opens investigation into Teva over 'improper' patents "There's blood in the water now," Kevin Noonan of the McDonnell Boehnen Hulbert & Berghoff law firm, who is a co-author of the Patent Docs blog. By Ed Silverman STAT+ | Supreme Court's gutting of Chevron doctrine could mean headaches for drug industry The weakening of the FDA's regulatory powers may lead to the one thing industry hates more than bad policy: uncertainty. By Nicholas Florko, Lizzy Lawrence, John Wilkerson, and Elaine Chen Opinion: Medicare should wait on approving coverage for new obesity drugs The new anti-obesity drugs have been tested in few older people. Medicare may be right not covering them until more is known about this group. By Alissa S. Chen Adobe STAT+ | Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines The actions were described in lawsuits filed by Gilead Sciences and Johnson & Johnson against Safe Chain and other wholesalers and pharmacies. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser